We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
76
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.5M 0.29%
352,424
– –
JAZZ icon
77
Jazz Pharmaceuticals
JAZZ
$15.9B
$7.44M 0.28%
67,456
– –
IOVA icon
78
Iovance Biotherapeutics
IOVA
$1.82B
$7.44M 0.28%
271,073
+50,000
+23% +$1.64M
GRTX
79
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$7.44M 0.28%
1,041,845
+625,179
+150% +$6.64M
SBRA icon
80
Sabra Healthcare REIT
SBRA
$5.34B
$7.37M 0.28%
510,660
– –
XRAY icon
81
Dentsply Sirona
XRAY
$2.68B
$7.11M 0.27%
161,287
+46,551
+41% +$1.97M
LTC
82
LTC Properties
LTC
$2.06B
$6.87M 0.26%
182,293
– –
WAT icon
83
Waters Corp
WAT
$37B
$6.71M 0.26%
37,184
+11,184
+43% +$2.11M
GH icon
84
Guardant Health
GH
$21.7B
$6.61M 0.25%
81,422
+57,766
+244% +$4.65M
FATE icon
85
Fate Therapeutics
FATE
$286M
$6.37M 0.24%
185,672
+20,000
+12% +$596K
SYNH
86
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$6.29M 0.24%
108,001
– –
TFX icon
87
Teleflex
TFX
$6.05B
$6.28M 0.24%
17,252
– –
PTCT icon
88
PTC Therapeutics
PTCT
$5.68B
$6.13M 0.23%
120,827
– –
NKTR icon
89
Nektar Therapeutics
NKTR
$2.39B
$6.09M 0.23%
17,539
– –
RCKT icon
90
Rocket Pharmaceuticals
RCKT
$340M
$6.05M 0.23%
289,029
+81,474
+39% +$1.47M
AMRN
91
Amarin Corp
AMRN
$299M
$5.88M 0.22%
42,479
+12,289
+41% +$1.69M
ZGNX
92
DELISTED
Zogenix, Inc.
ZGNX
$5.82M 0.22%
215,406
– –
APLS
93
DELISTED
Apellis Pharmaceuticals
APLS
$5.67M 0.22%
173,494
– –
CRSP icon
94
CRISPR Therapeutics
CRSP
$4.73B
$5.6M 0.21%
76,222
– –
CERN
95
DELISTED
Cerner Corp
CERN
$5.59M 0.21%
81,500
– –
ARNA
96
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.54M 0.21%
88,002
+60,000
+214% +$3.3M
INO icon
97
Inovio Pharmaceuticals
INO
$55.7M
$5.45M 0.21%
+16,837
New +$2.7M
BMY.RT
98
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$5.28M 0.2%
1,473,710
– –
BLUE
99
DELISTED
bluebird bio
BLUE
$5.14M 0.2%
6,500
– –
FOLD
100
DELISTED
Amicus Therapeutics
FOLD
$5.08M 0.19%
336,984
-31,976
-9% -$390K
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.